Slide

Novel, innovative, and targeted medicines to improve outcomes for cancer patients

IL-21 AGONIST
Slide

Previous studies have shown that modulating IL-21 activity can enhance immunotherapy

MODULATING IL-21 ACTIVITY
Learn more
Slide

Pio Therapeutics is developing a first-in-class agonistic antibody to IL-21

IL-21 AGONIST ANTIBODY
Learn more

Agonist antibody
to IL-21 for oncology

First-in-class mechanism
of action

Validated in vitro functional assays

Robust IP portfolio

Proof of concept data
with in vivo preclinical models

Defined toxicology and regulatory pathway

Clear application to oncology as an unmet medical need

About us

Amplifying success in immunotherapy

When harnessed appropriately, the immune system is an extremely potent and specific endogenous anti-tumour mechanism. Our first-in-class agonist antibody has been designed to address current clinical challenges associated with immunotherapy such as improving the rate and quality of responses, while also addressing the clinical challenges that have been encountered with recombinant IL-21.

Our mission

Novel, innovative, targeted medicines

Our mission is to develop novel, innovative and targeted medicines that augment endogenous anti-tumour immunity to further improve outcomes for patients affected by cancer.

Our leaders

Pio Tx’s team brings decades of global scientific and commercial expertise, with proven success in therapeutic discovery, preclinical, clinical, regulatory and commercial stages of drug development.

Damien Bates

MD PhD FRACS MBA
Chief Executive Officer & Managing Director

Christopher Chan

PhD

Chief Scientific Officer

Linda Peterson

BSc Grad Cert BA
Chief Operating Officer & Company Secretary

Damien Bates

MD PhD FRACS MBA
Chief Executive Officer & Managing Director

Christopher Chan

PhD

Chief Scientific Officer

Linda Peterson

BSc Grad Cert BA
Chief Operating Officer & Company Secretary

Science

Immunotherapy has revolutionised cancer treatment, however there are challenges to its efficacy.

Pio Tx is developing a selective agonistic anti-IL-21 monoclonal antibody that has been designed to amplify the bioactivity of endogenously produced IL-21, proportional to its localized expression. This approach will overcome clinical challenges associated with recombinant IL-21, take advantage of an antibody as a therapeutic modality, and allow combinatorial approaches with other therapeutics to be easily developed.